FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jianqin Shan

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Philadelphia Chromosome

Procedures

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Wei-Gang Tong; William Wierda; Gautam Borthakur; Carlos Bueso-Ramos; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Jianqin Shan; Guillermo Garcia-Manero
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Jorge Cortes
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Alfonso Quintás-Cardama; Jianqin Shan; Srdan Verstovsek; Lynne V Abruzzo; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jorge Cortes
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jianqin Shan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Wei-Gang Tong; William Wierda; Gautam Borthakur; Carlos Bueso-Ramos; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Jianqin Shan; Guillermo Garcia-Manero
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Cancer 2012;118(18):4462-70.
2012: Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Jorge Cortes
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Cancer 2012;118(12):3116-22.
2011: Alfonso Quintás-Cardama; Jianqin Shan; Srdan Verstovsek; Lynne V Abruzzo; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jorge Cortes
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Cancer 2011;117(22):5085-93.
2011: Elias Jabbour; Hagop M Kantarjian; Susan O'Brien; Alfonso Quintás-Cardama; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Jorge E Cortes
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4260-5.
2011: Kiran Naqvi; Guillermo Garcia-Manero; Sagar Sardesai; Jeong Oh; Carlos E Vigil; Sherry Pierce; Xiudong Lei; Jianqin Shan; Hagop M Kantarjian; Maria E Suarez-Almazor
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2240-6.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Gautam Borthakur; Farhad Ravandi; Srdan Verstovsek; Jianqin Shan; Jorge Cortes
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Haematologica 2011;96(6):918-21.
2011: Aref Al-Kali; Hagop Kantarjian; Jianqin Shan; Roland Bassett; Alfonso Quintás-Cardama; Gautam Borthakur; Elias Jabbour; Srdan Verstovsek; Susan O'Brien; Jorge Cortes
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Cancer 2011;117(2):327-35.
2010: Farhad Ravandi; Jorge Cortes; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Fabio P S Santos; Jianqin Shan; Mark Brandt; Marcos De Lima; Sherry Pierce; Hagop Kantarjian
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
Blood 2010;116(26):5818-23; quiz 6153.
2010: Andrew Lamb; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William G Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
Blood 2010;116(22):4422-9.
2010: Wei-Gang Tong; Andrew Lamb; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Gautam Borthakur; Jianqin Shan; Sherry Pierce; Mary Beth Rios; Jorge Cortes
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Cancer 2010;116(13):3152-9.
2010: Dushyant Verma; Andrew Lamb; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guillermo Garcia-Manero; Charles Koller; Gautam Borthakur; Jorge Cortes
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Cancer 2010;116(11):2673-81.
2010: Lanlan Shen; Andrew Lamb; Yi Guo; Edward Lin; Jianqin Shan; Xuelin Huang; Donald Berry; Saira Ahmed; Wei Zhu; Sherry Pierce; Yutaka Kondo; Yasuhiro Oki; Jaroslav Jelinek; Hussain Saba; Eli Estey; Jean-Pierre J Issa
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):605-13.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Marina Konopleva; Alessandra Ferrajoli; Tapan Kadia; Gautam Borthakur; Denise Stigliano; Jianqin Shan; Andrew Lamb
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):392-7.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Andrew Lamb
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):398-404.
2009: Farhad Ravandi; Jean-Pierre J Issa; Guillermo Garcia-Manero; Susan O'Brien; Sherry Pierce; Jianqin Shan; Gautam Borthakur; Srdan Verstovsek; Stefan Faderl; Jorge Cortes; Andrew Lamb
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Cancer 2009;115(24):5746-51.
2009: Andrew Lamb; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl; Carlos E Bueso-Ramos; Lynne V Abruzzo; Sherry Pierce; Jianqin Shan; Jean-Pierre J Issa; Guillermo Garcia-Manero
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Cancer 2009;115(22):5202-9.
2009: Yesid Alvarado; Andrew Lamb; Susan O'Brien; Stefan Faderl; Gautam Borthakur; Jan Burger; Jan A Burger; Guillermo Garcia-Manero; Jianqin Shan; Jorge Cortes
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Cancer 2009;115(16):3709-18.
2009: Hagop M Kantarjian; Jianqin Shan; Daniel Jones; Susan O'Brien; Mary Beth Rios; Elias Jabbour; Jorge Cortes
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3659-63.
2009: Carmen Fava; Hagop M Kantarjian; Elias Jabbour; Susan O'Brien; Nitin Jain; Mary Beth Rios; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Jianqin Shan; Jorge Cortes
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2008: Andrew Lamb; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan F List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre J Issa; Emil J Freireich; Guillermo Garcia-Manero
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer 2008;113(6):1351-61.
2008: Constantine S Tam; Andrew Lamb; Guillermo Garcia-Manero; Gautam Borthakur; Susan O'Brien; Farhad Ravandi; Jianqin Shan; Jorge Cortes
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Blood 2008;112(3):516-8.
2008: Guillermo Garcia-Manero; Jianqin Shan; Stefan Faderl; Jorge Cortes; Farhad Ravandi; Gautam Borthakur; William G Wierda; Sherry Pierce; Elihu Estey; Jinsong Liu; X Huang; Andrew Lamb
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia 2008;22(3):538-43.
2008: Andrew Lamb; Susan O'Brien; Jianqin Shan; Xuelin Huang; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi-Kashani; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Cancer 2008;112(4):837-45.
2007: Jorge Cortes; Elias Jabbour; Andrew Lamb; C Cameron Yin; Jianqin Shan; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Megan Breeden; Nubia Reeves; William G Wierda; Dan Jones
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Blood 2007;110(12):4005-11.
2007: Elias Jabbour; Hagop M Kantarjian; Lynne V Abruzzo; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2007;110(8):2991-5.
2007: Andrew Lamb; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Francis Giles; Jorge Cortes
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Hagop M Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Jianqin Shan; Jan Davisson; Carlos E Bueso-Ramos; Jean-Pierre J Issa
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Cancer 2007;109(6):1133-7.
2007: Ahmed Aribi; Gautam Borthakur; Farhad Ravandi; Jianqin Shan; Jan Davisson; Jorge Cortes; Andrew Lamb
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Cancer 2007;109(4):713-7.
2007: Hagop M Kantarjian; Susan O'Brien; Jianqin Shan; Ahmed Aribi; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Jan Davisson; Jean-Pierre J Issa
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Cancer 2007;109(2):265-73.
2006: Alfonso Quintas-Cardama; Andrew Lamb; Susan O'Brien; Elias Jabbour; Francis Giles; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Jianqin Shan; Srdan Verstovsek; Jorge Cortes
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Daniel Jones; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Francis Giles; Srdan Verstovsek; Guillermo Garcia-Manero; Deborah Thomas; Farhad Ravandi; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Elias Jabbour; Jianqin Shan; Susan O'Brien; Maher Albitar; Andrew Lamb
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos E Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Andrew Lamb
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Jorge E Cortes; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Hagop M Kantarjian
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Andrew Lamb; Miloslav Beran; Jorge Cortes; Susan O'Brien; Francis Giles; Sherry Pierce; Jianqin Shan; William Plunkett; Michael Keating; Elihu Estey
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Andrew Lamb; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William G Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2005: Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; William G Wierda; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Francis Giles; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Carlos E Bueso-Ramos; Jianqin Shan; Sherry Pierce; Guillermo Garcia-Manero; Michael Keating; Andrew Lamb
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianqin Shan; Jorge Cortes
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Jianqin Shan; Mary Beth Rios; Richard Champlin; Marcos De Lima; Jorge Cortes
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Jorge Cortes; Moshe Talpaz; Susan O'Brien; Dan Jones; Rajyalakshmi Luthra; Jianqin Shan; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Mary Beth Rios; Andrew Lamb
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2004: Andrew Lamb; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Cancer 2004;101(12):2788-801.
2004: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Rajyalakshmi Luthra; Francis Giles; Srdan Verstovsek; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Dan Jones; Moshe Talpaz
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Francis Giles; Mary Beth Rios; Jianqin Shan; Laurie Letvak; Deborah Thomas; Stefan Faderl; Alessandra Ferrajoli; Jorge Cortes
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: Andrew Lamb; Susan O'Brien; Jorge Cortes; Francis Giles; Jianqin Shan; Mary Beth Rios; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; William G Wierda; Steven M Kornblau; Alessandra Ferrajoli; Michael Keating; Moshe Talpaz
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; William G Wierda; Michael Keating; Moshe Talpaz
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Andrew Lamb; Susan O'Brien; Jorges Cortes; Jianqin Shan; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Mary Beth Rios; Moshe Talpaz
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqin Shan; Deborah Thomas; Michael Andreeff; Steven M Kornblau; Stefan Faderl; Guillermo Garcia-Manero; Kevin White; Susie Mallard; Emil J Freireich; Hagop M Kantarjian
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Jean-Pierre J Issa; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Michael Andreeff; Michael Keating; Moshe Talpaz
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Jorge E Cortes; Moshe Talpaz; Francis Giles; Susan O'Brien; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Stefan Faderl; Deborah A Thomas; William G Wierda; Alessandra Ferrajoli; Sima Jeha; Hagop M Kantarjian
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis Giles; Mary Beth Rios; Stefan Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Sergio Giralt; Mary Beth Rios; Jianqin Shan; Francis Giles; Deborah A Thomas; Stefan Faderl; Marcos De Lima; Guillermo Garcia-Manero; Richard Champlin; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Terry L Smith; Francis Giles; Stefan Faderl; Deborah A Thomas; Guillermo Garcia-Manero; Jean-Pierre J Issa; Michael Andreeff; Steven M Kornblau; Charles Koller; Miloslav Beran; Michael Keating; Mary Beth Rios; Jianqin Shan; Debra Resta; Renaud Capdeville; Kimberly Hayes; Maher Albitar; Emil J Freireich; Jorge E Cortes
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Terry L Smith; Mary Beth Rios; Jianqin Shan; Ying Yang; Francis Giles; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; William G Wierda; Jean-Pierre J Issa; Steven M Kornblau; Michael Keating; Debra Resta; Renaud Capdeville; Moshe Talpaz
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Hagop M Kantarjian; Jorge Cortes; Susan O'Brien; Francis Giles; Maher Albitar; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Debra Resta; Moshe Talpaz
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Susan O'Brien; Moshe Talpaz; Jorge Cortes; Jianqin Shan; Francis Giles; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Susie Mallard; Mary Beth; Charles Koller; Steven M Kornblau; Michael Andreeff; Anthony J Murgo; Michael Keating; Hagop M Kantarjian
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2001: Hagop M Kantarjian; Jianqin Shan; Terry Smith; Moshe Talpaz; Peter Kozuch; Mary Beth Rios; Jorge Cortes; Francis Giles; Susan O'Brien
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Moshe Talpaz; Susan O'Brien; E Rose; S Gupta; Jianqin Shan; Jorge Cortes; Francis Giles; Stefan Faderl; Hagop M Kantarjian
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.